BRISAR: Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry (ISAR)
As part of a larger endeavour to better characterize the international severe asthma population, this study looked to describe the differential expression of the various cellular pathways involved in the pathogenesis of this disease. Patients were evaluated by their levels of key biomarkers (pre-biologic initiation) and a high degree of overlap was observed. Furthermore, distinct patient clusters with associated clinical characteristics were identified.
The findings of this study enable severe asthma phenotypes to be easily distinguished, which may aid in the delivery of precision medicine. Beyond that, it suggests that rather than relying on simple biomarker positivity, a more comprehensive approach – rather than relying on simple biomarker positivity – may be needed to identify the best therapy for patients.
ISAR: Protocol for a Global Registry
Due to the heterogeneity of the severe asthma population, severe asthma exerts a disproportionate burden on patients and healthcare worldwide. To aid in this endeavour, ISAR aims to describe the protocol for registry development and management, the rationale behind each step, and the potential benefits of ISAR to the adult severe asthma population.
ISAR: Mission Statement
ISAR aims to improve the care of severe asthma patients by combining existing knowledge with new research. By examining real-world data on the efficacy and safety of different treatment options, we hope to make a positive impact on patient care. Check out our mission statement to learn more about what we hope to accomplish.